ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2189

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository (“Registry”) Prospective Follow-up Analysis: One-Year First and Recurrent Thrombosis Risk

Doruk Erkan1, Stephane Zuily2, Alessandra Banzato3, Karel De Ceulaer4, Hannah Cohen5, Maria Tektonidou6, Danieli Andrade7 and , on Behalf of APS ACTION .8, 1Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, 2Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Unit, Vandoeuvre-Les-Nancy, France, 3Department of Cardiac Thoracic and Vascular Sciences, (2) Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua Italy, Padua, Italy, 4Internal Medicine, University of the West Indies, Kgn 7, Jamaica, 5Hematology., University College London, LOndon, United Kingdom, 6First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, 7Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, 8., New York, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ,

Session Information

Date: Tuesday, November 10, 2015

Title: Antiphospholipid Syndrome: Clinical

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: APS ACTION “Registry” was
created to study the natural course of disease over 10 years in persistently
antiphospholipid antibody (aPL)-positive patients with/without other systemic
autoimmune diseases. Given that risk-stratified prospective data on the first
or recurrent thrombosis risk in persistently aPL-positive patients are limited
and controversial, our objective was to describe the thrombotic events
identified during the follow-up of APS ACTION “Registry” patients, and also to determine
the one-year first and recurrent thrombosis risk.

Methods: A web-based data capture system
is used to store patient demographics, aPL-related history, and medications.
The inclusion criteria are positive aPL (lupus anticoagulant test [LA], anticardiolipin
antibody [aCL], and/or anti-β2Glycoprotein-I antibody [aβ2GPI])
based on the Updated Sapporo Classification Criteria at least twice within one
year prior to enrollment. Patients are followed every 12±3 months with clinical
data and blood collection; they also receive advice on cardiovascular disease
and thrombosis prevention at each visit. In this descriptive analysis, patients
who completed their one year follow-up visits are included. 

Results: Of 581 patients included in the APS
ACTION Registry, 350 (60%) completed their one year follow-up visits as of June
2015 (aPL/APS without any other autoimmune disease: 241 [no thrombosis: 35;
thrombotic APS: 148; obstetric APS: 24; and thrombotic & obstetric APS:
34]; and aPL/APS associated with another autoimmune disease: 109 [no
thrombosis: 45; thrombotic APS: 42; obstetric APS: 10; and thrombotic &
obstetric APS: 12]). Table demonstrates the demographic, clinical, and
laboratory characteristics of patients who had new events during the one year follow-up.
Based on five new thrombotic events, the incident thrombosis risk was 1.7% and 0%
per year in patients with and without history of thrombosis, respectively.

Conclusion: The one year incident thrombosis
risk is relatively low and commonly associated with triple aPL-positivity as
well as non-aPL thrombosis risk factors in our multi-center international cohort.
Annual and risk stratified analysis of APS ACTION registry will better determine
the risk of thrombosis in persistently aPL-positive patients based on different
risk profiles.

Disclosure: D. Erkan, New York Community Trust, 2,APS ACTION Executive Committee Co-Chair, 6; S. Zuily, None; A. Banzato, None; K. De Ceulaer, None; H. Cohen, None; M. Tektonidou, None; D. Andrade, None; O. B. O. A. A. ., None.

To cite this abstract in AMA style:

Erkan D, Zuily S, Banzato A, De Ceulaer K, Cohen H, Tektonidou M, Andrade D, . OBOAA. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository (“Registry”) Prospective Follow-up Analysis: One-Year First and Recurrent Thrombosis Risk [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/antiphospholipid-syndrome-alliance-for-clinical-trials-and-international-networking-clinical-database-and-repository-registry-prospective-follow-up-analysis-one-year-first-and-recurrent-thrombosi/. Accessed .

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antiphospholipid-syndrome-alliance-for-clinical-trials-and-international-networking-clinical-database-and-repository-registry-prospective-follow-up-analysis-one-year-first-and-recurrent-thrombosi/